Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 5/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | HINT1 | P49773 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891135 | 0.82 | ADCY5 (0.47) | — | |
| SCHEMBL3912998 | 0.79 | NT5E (0.37) | ABCB1NT5EHSP90AA1HSP90AB1AHCY | |
| SCHEMBL3910024 | 0.79 | NT5E (0.37) | ABCB1NT5EHSP90AA1HSP90AB1AHCY | |
| SCHEMBL4897999 | 0.79 | ABCB1 (0.33) | ABCB1NT5ENR1I2ALBPDE4D | |
| SCHEMBL9684332 | 0.78 | NT5E (0.44) | ABCB1NT5EPDE4DHSP90AA1HSP90AB1 | |
| SCHEMBL887526 | 0.74 | NT5E (0.54) | NT5EPDE4D | |
| SCHEMBL21545820 | 0.74 | NT5E (0.54) | NT5EPDE4D | |
| SCHEMBL21959765 | 0.74 | LMNA (0.49) | NT5EPDE4D | |
| SCHEMBL10022904 | 0.74 | NT5E (0.54) | NT5EPDE4D | |
| SCHEMBL27527275 | 0.74 | ADCY5 (0.43) | ABCB1NT5ENR1I2ALBPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA VZW (BE) | 2008-07-24 | — | — | US | claimed |
| EP-1210347-B1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA V Z W (BE) | 2004-06-23 | — | — | EP | claimed |
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA VZW (BE) | 2008-07-24 | — | — | US | disclosed |
| EP-1210347-B1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA V Z W (BE) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | ATIC, ADORA2A, ADORA3 | ABCB1 328/4885NT5E 272/4885NR1I2 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.